Evofem BiosciencesEVFM -0.06% Operating Margin % is -508.23% as of Mar. 2026. The stock has 5 warning signs investors should review. Among 945 Biotechnology companies, Evofem Biosciences ranks better than 64.34% on this metric.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Evofem Biosciences Operating Margin % Related Terms
Evofem Biosciences Operating Margin % Historical Data
* Premium members only.
The historical data trend for Evofem Biosciences's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EVFM vs PTIX, ATXI, AGTX: Operating Margin % Comparison
For the Biotechnology subindustry, Evofem Biosciences's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evofem Biosciences Operating Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Evofem Biosciences's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Evofem Biosciences's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Evofem Biosciences's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evofem Biosciences (EVFM) has a Operating Margin % of -508.23% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Evofem Biosciences and its competitors. According to the industry distribution chart, Evofem Biosciences ranks #337 out of 945 companies in the Biotechnology industry, placing it in the top 35.7%.
Is Evofem Biosciences' Operating Margin % too high?
Evofem Biosciences' current Operating Margin % is -508.23%. Based on the distribution chart, Evofem Biosciences ranks #337 out of 945 companies in the Biotechnology industry, which is above the industry midpoint.
How does Evofem Biosciences' Operating Margin % compare to PTIX and ATXI?
According to the Biotechnology industry distribution chart, Evofem Biosciences ranks #337 out of 945 companies for Operating Margin %. This puts Evofem Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Evofem Biosciences and its competitors. Evofem Biosciences's current Operating Margin % is -508.23%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evofem Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Evofem Biosciences (EVFM) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 12.8% below its estimated fair value. The current Operating Margin % is -508.23%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Evofem Biosciences (EVFM), the current Operating Margin % is -508.23% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EVFM has been successfully added to your 